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Background: Rhabdoid tumors are highly aggressive malignancies affecting infants and very young children. In
many instances these tumors are resistant to conventional type chemotherapy necessitating alternative approaches.
Methods: Proliferation assays (MTT), apoptosis (propidium iodide/annexin V) and cell cycle analysis (DAPI), RNA
expression microarrays and western blots were used to identify synergism of the HDAC (histone deacetylase)
inhibitor SAHA with fenretinide, tamoxifen and doxorubicin in rhabdoidtumor cell lines.
Results: HDAC1 and HDAC2 are overexpressed in primary rhabdoid tumors and rhabdoid tumor cell lines.
Targeting HDACs in rhabdoid tumors induces cell cycle arrest and apoptosis. On the other hand HDAC inhibition
induces deregulated gene programs (MYCC-, RB program and the stem cell program) in rhabdoid tumors. These
programs are in general associated with cell cycle progression. Targeting these activated pro-proliferative genes by
combined approaches of HDAC-inhibitors plus fenretinide, which inhibits cyclinD1, exhibit strong synergistic effects
on induction of apoptosis. Furthermore, HDAC inhibition sensitizes rhabdoid tumor cell lines to cell death induced
by chemotherapy.
Conclusion: Our data demonstrate that HDAC inhibitor treatment in combination with fenretinide or conventional
chemotherapy is a promising tool for the treatment of chemoresistant rhabdoid tumors.Background
Altered states of chromatin in cancer cells are a promising
novel target for therapeutic strategies in the treatment of
malignant tumors. Two of many important mechanisms
of epigenetic regulation are DNA methylation and histone
acetylation, which are closely connected and deregulated
in many malignancies [1,2]. HDAC inhibitors counteract
cell proliferation and induce apoptosis by altering histone
tails and non-histone targets including transcription factors,
hormone receptors, signal transducers and molecular
chaperones [3]. Recent investigations demonstrated that
HDAC-inhibitors (HDACi) display selective toxicity against* Correspondence: michael.fruehwald@klinikum-augsburg.de
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reproduction in any medium, provided the ortumor cells and sensitize cancer cells to the cytotoxic
effects of conventional cytostatic drugs [4-6]. These
characteristics have led to the use of several HDACi in a
number of single agent or combinatorial clinical trials
(more than 100 currently listed) (e.g. in lung, breast
bladder cancer, glioblastoma, leukemias and lymphomas)
[7,8]. Recently the importance of deregulation of
epigenetic mechanisms in the development of embryonal
tumors such as medulloblastoma, CNS PNET and AT/RT
has been demonstrated. Epigenetically active compounds
including histone deacetylase inhibitors (HDACi) and
demethylating agents (e.g. azacitidine) have been identified
as attractive tools for the treatment of embryonal tumors,
including rhabdoid tumors [9-11].
Rhabdoid tumors are rare but highly aggressive
neoplasms with an incidence peaking between birth
and 3 years of age [12]. Rhabdoid tumors of the brain are. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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however rhabdoid tumors can also be found in soft
tissues (MRT, malignant rhabdoid tumors) and the
kidneys (RTK, rhabdoid tumor kidney). Outcome
especially for the youngest patients with rhabdoid
tumors remains bleak despite the use of aggressive
multimodal chemotherapeutic, radiotherapeutic and
surgical interventions (2-year survival rates between
15% to 55% for children with AT/RT) [13,14]. The majority
of rhabdoid tumors exhibit biallelic alterations in the
tumor suppressor gene SMARCB1. Apart from SMARCB1
mutations only very few and rather infrequent further
alterations have been detected [15,16]. Some pathways
drivingoncogenesis are defined in rhabdoid tumors: In
SMARCB1 negative tumors oncogenes (including MYC
and CYCLIND1) [17-20] and tumor cascades such as the
sonic hedgehog pathway are activated [19]. Furthermore,
SMARCB1 acts as a direct repressor of the polycomb
complex subunit EZH2 [21]. SMARCB1 and EZH2
exhibit antagonistic functions in the regulation of stem cell-
associated programs. In rhabdoid tumors loss of SMARCB1
activates those programs [21].
Here we demonstrate that several HDACs, including
HDAC1 and 2, are overexpressed in primary rhabdoid
tumors and tumor cell lines. The histone deacetylase
inhibitor (HDACi) SAHA inhibits cell proliferation of
rhabdoid tumor cells by inducing a reversible G2-arrest and
subsequently apoptosis. Interestingly SAHA activates tumor
pathways, which are already deregulated in rhabdoid
tumors (such as MYC, CYCLIND and the pluripotency
associated program controlled by EZH2). Based on these
results we developed a targeting strategy combining SAHA
with fenretinide, which suppresses cyclinD1, and SAHA
with conventional chemotherapy. These combinations
showed strong synergistic effects on tumor cell growth and
represent a promising potential tool for the treatment of
rhabdoid tumors.
Methods
Cell lines
Rhabdoid tumor cell lines BT12 and BT16 (AT/RT),
G401 (rhabdoid tumor of the kidney (RTK)) and
A204 (rhabdoid tumor of the liver) were cultured in
DMEM high glucose formulation (Invitrogen, Karlsruhe,
Germany), supplemented with 10% fetal bovine serum
(South American, Invitrogen), 2% glutamine (Invitrogen,
Karlsruhe, Germany) and no additional antibiotics. The
cells were cultured at 37°C in a humidified atmosphere
with 5% CO2. A204 and G401 were obtained from ATCC.
BT12 and BT16 were a gift from Dr. P. Houghton. Mouse
embryonic stem cell (ESC) line OG2 was cultured to the
distributors recommendation in DMEM with Glutamax,
non-essential aminoacids, mercaptoethanol, PenStrep
(all PAA Laboratories, Pasching, Austria) and LIF. Fordifferentiation of ESCs OG2 cells were cultured at
least five days without LIF. OG2 cell line was a gift from
Hans Schöler (MPI Muenster, Germany).
The identity of all cell lines was verified using ST-PCR.
All experiments using cell lines in this publication were
at least performed using three independent replicates.Histone deacetylase inhibitors, Cyclin D inhibitors and
chemotherapy
Suberoylanilindehydroxamic acid (SAHA) (Merck,
Darmstadt, Germany), Trichostatin A (TSA) (Sigma,
Taufkirchen, Germany), N-(4-hydroxyphenyl)retinamide
(4-HPR or fenritinide) (ONBIO, Ontario, Canada, #
65646-68-6) and 4-Hydroxy-Tamoxifen (4OH-Tam) (Sigma
Taufkirchen, Germany, # H7904) were reconstituted in
100% ethanol, as a 10 mM solutions. M344 was synthesized
by one of us (M.J.). Doxorubicin was purchased from Merck
(Merck Millipore, Darmstadt, Germany # 324380).Cytotoxicity assay
Cell suspensions (5,000 cells/100 μl) were seeded into
four 96-well-plates. Cells were allowed to reach exponential
growth before 100 μl of cell culture medium containing the
drugs at different concentrations were added. Each drug
concentration (0, 0.01, 0.1, 1, 10 and 100 μM) was tested in
3 biological replicates. For experiments with combined
treatment we used compound 1 (see Tables 1 and 2) in
increasing concentrations as in single compound
experiments (0, 0.01, 0.1, 1, 10 and 100 μM). Compound 2
was used at 1/10 of the concentration of compound 1.
After 0, 24, 48 and 72 hr cells were incubated 3 hr with
10 μl MTT reagent (5 mg/ml MTT dissolved in PBS).
Metabolically active cells cleaved the yellow tetrazolium
salt to a purple formazan dye. A decrease in the number of
living cells correlated with the number of purple formazan
crystals. Crystals were dissolved in 100μllysis buffer. The
specimen was evaluated spectrophotometrically at 570 nm
and a reference of 650 nm using a Multiskan Ascent
multiplate reader (Labsystems, Helsinki, Finland).Analysis of combined drug effects on cytotoxicity
To evaluate drug combination effects we analyzed cytotox-
icity assay data using the median effect method by Chou
and Talalay [22]. We employed three biological replicates of
the cytotoxicity assay for each experiment. The fraction of
unaffected cells was defined as the proportion of living cells
compared to the control. The combination index indicates
synergism if CI < 1, antagonism for CI > 1 and an additive
effect for CI = 1. Values of the CI were determined at
the IC50 concentration (fraction affected = 0.5). The
method was implemented in the statistical software R
(Version 2.15.1).
Table 1 Summarizes results of MTT-tests in different rhabdoid tumor cell lines (A204, G401, BT16) treated with
HDAC-inhibitors (SAHA, TSA, M344) cyclin D inhibitors (fenretinide, tamoxifen) as single compounds and in combinations
of both classes of compounds
Cell line Compound 1 Compound 2 IC 50 μM m CI R2
A204 SAHA ————————————— 24.72 0.6 ————————————— 0.72
A204 M344 ————————————— 128.76 0.57 ————————————— 0.67
A204 TSA ————————————— 1.83 0.43 ————————————— 0.87
A204 Tam ————————————— 2.67 0.5 ————————————— 0.86
A204 Fen ————————————— 1.87 0.4 ————————————— 0.84
A204 SAHA Tam 0.97 0.36 0.07 0.75
A204 SAHA Fen 1.25 0.48 0.1 0.72
A204 M344 Tam 0.97 0.48 0.19 0.56
A204 M344 Fen 0.28 0.24 0.01 0.88
A204 TSA Tam 0.16 0.2 0.08 0.77
A204 TSA Fen 0.1 0.24 0.05 0.73
G401 SAHA ————————————— 31.82 0.44 ————————————— 0.87
G401 Tam ————————————— 3.13 0.53 ————————————— 0.89
G401 Fen ————————————— 3.37 0.54 ————————————— 0.85
G401 SAHA Tam 1.42 0.3 0.06 0.9
G401 SAHA Fen 1.65 0.54 0.09 0.91
BT16 SAHA ————————————— 8.39 0.64 ————————————— 0.93
BT16 Tam ————————————— 2.09 0.75 ————————————— 0.9
BT16 Fen ————————————— 2.74 0.5 ————————————— 0.91
BT16 SAHA Tam 0.11 0.44 0.02 0.87
BT16 SAHA Fen 0.43 0.52 0.06 0.86
Table shows results after 72 h of treatment.
CI = combination index [22].
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For differentiation of mouse embryonic stem cell line
OG2 cells were grown without LIF. After 5d cells were
harvested and lysed using Biorupture (Diagenode; Liege,
Belgium). SDS page was performed as described [9].
Briefly tris/glycine gels were used for 1-D separation
(20 mg protein per lane). Semidry transfer was carried outTable 2 Summarizes results of MTT-tests in different rhabdoid
HDAC-inhibitors (SAHA, TSA, M344) or doxorubicin as single
Cell line Compound 1 Compound 2
A204 SAHA —————————————
A204 DOXO —————————————
A204 DOXO SAHA
G401 SAHA —————————————
G401 DOXO —————————————
G401 DOXO SAHA
BT16 SAHA —————————————
BT16 DOXO —————————————
BT16 DOXO SAHA
The CI values have been determined at the respective IC50 concentration. CI < 1 ind
regression in the median effect plot.for 1 h at 18 V using tris/glycine buffer [9]. Western-blots
were scanned and aligned with the Photoshop 6.0 channel
mixer (Adobe).
Antibodies for western blots
Hdac1 (ab7028) rabbit polyclonal 65 kDA, 1:500, (Abcam,
Cambridge UK)tumor cell lines (A204, G401, BT16) treated with
compounds or in combinations of both compounds
IC 50 μM m CI R2
24.72 0.6 ————————————— 0.72
6.48 0.37 ————————————— 0.72
0.16 0.22 0.02 0.76
31.82 0.44 ————————————— 0.87
0.67 0.38 ————————————— 0.77
0.03 0.17 0.03 0.85
8.39 0.64 ————————————— 0.93
0.13 0.18 ————————————— 0.83
0.003 0.2 0.02 0.81
icates synergism. R2 denotes the coefficient of determination of the linear
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(Abcam, Cambridge UK)
α-Tubulin (sc 23948) mouse monoclonal, 50–55 kDa,
1:1000, (Santa Cruz, Heidelberg, Germany)
Oct4 (sc-8628) goat polyclonal, 43–50 kDa, 1:500,
(Santa Cruz, Heidelberg, Germany)
CyclinD1 (sc 754), rabbit polyclonal, 38 kDa, 1:500,
(Santa Cruz, Heidelberg, Germany)
H3K27me3 (6002), mouse monoclonal, 18 kDa, 1:500,
(Abcam, Cambridge UK)
Ezh2 (AC22), mouse monoclonal, 98 kDa, 1:500,
(Cell Signaling, Danvers, USA)
Apoptosis detection and cell cycle analysis
Effects on apoptosis induction were analyzed in A204
cells. Cells were incubated in 75 cm2 tissue flasks with
the drugs for 24, 48 and 72 hr. A204 cells were treated
with ethanol (control), with SAHA (1 μM or 10 μM),
fenretinide (1 μM or 10 μM) or a combination of SAHA
(1 μ or 10 μM) and fenretinide (1 μM or 10 μM). All
experiments were at least performed in biological trip-
licates. An annexin-V-FITC apoptosis detection kit was
employed (BD Biosciences, Heidelberg, Germany). Cells
were washed with PBS and fluorescein isothiocyanate-
conjugated annexin-V and propidiumiodide were added.
Cells were then incubated at room temperature (15 min)
and analyzed by flowcytometry, using a Facscalibur (BD
Biosciences, Heidelberg, Germany). For cell cycle analysis
cells were cultured and treated with compounds as
described before, incubated with DAPI and measured using
the Facscalibur(BD Biosciences, Heidelberg, Germany).
cDNA microarray experiments and statistical analysis
A204 cells were treated with 10 μmol SAHA or equal
amounts of ethanol (control). SAHA treated A204 cells and
control samples were used as biological triplicates. After
12 h incubation cells were harvested and RNA was isolated
by using an RNAeasy mini kit (Qiagen, Hilden, Germany).
Affymetrix Gene Chip human 1.0 was used. Microarray
data were analyzed using GeneSpring GX Software (Agilent,
Santa Clara, USA). Microarray data complywiththe MIAME
standard. Data were corrected for background noise,
normalized and summarized using ExonRMA16 Algorithm.
Following quality control was performed.
To identify differentially expressed genes in SAHA
treated compared to untreated A204 cells we used an
unpaired t-test. For further analysis we considered genes
with a students t-test p-value of < 0.05 and a foldchange
of ≥ 2. Prior published microarray data were used as
supplied, as processed lists or downloaded from GEO
[23,24]. Analysis of enriched GeneSets with GSEA
(http://www.broadinstitute.org/gsea/index.jsp). GeneSets
were downloaded from the MSig database [23,24]. To
process the data, in-house scripts were employed.For analysis of HDAC RNA expression we compared
available data from geo database of primary rhabdoid
tumors [25] to expression data from normal brain tissue
[26]. These data were MAS5.0 normalized. HDACs in
primary rhabdoid tumor were compared to normal brain
tissue from different localizations of the brain.
Microarray data were confirmed using real-time qPCR
(Step One plus, Applied Biosystem, Carlsbald, USA).
RNA was isolated as described above from G401 cell
treated with SAHA for 12 h. RT-PCR was performed
using Takara RT-PCR kit (Clontec Laboratories, Mountain
View, USA) according to the manufacturer’s protocol. For
Real-time PCR we used Fast SYBR green (Applied
Biosystem, Carlsbad, USA).
Primers used for real-time PCR
hHMGB2 for: CGG-GGC-AAA-ATG-TCC-TCG-TA
hHMGB2rev: CGG-AAG-AGT-CCG-GGT-GTT-T
hBLM for: CAG-ACT-CCG-AAG-GAA-GTT-GTA-TG
hBLM rev: TTT-GGG-GTG-GTG-TAA-CAA-ATG-AT
hRFC3 for: GTG-GAC-AAG-TAT-CGG-CCC-TG
hRFC3 rev: TGA-TGG-TCC-GTA-CAC-TAA-CAG-AT
hMELK for: TCT-CCC-AGT-AGC-ATT-CTG-CTT
hMELK rev: TGA-TCC-AGG-GAT-GGT-TCA-ATA-GA
hMCM4 for: GAC-GTA-GAG-GCG-AGG-ATT-CC
hMCM4 rev: GCT-GGG-AGT-GCC-GTA-TGT-C
hMCM7 for: CCT-ACC-AGC-CGA-TCC-AGT-CT
hMCM7 rev: CCT-CCT-GAG-CGG-TTG-GTT-T
hPOLD3 for: GAG-TTC-GTC-ACG-GAC-CAA-AAC
hPOLD3 rev: GCC-AGA-CAC-CAA-GTA-GGT-AAC
Results
HDACs are highly expressed in primary rhabdoid tumors
and rhabdoid tumor cell lines
Aberrant expression of different HDACs has been
observed in various tumors [1,2,9] and has been linked
to tumor growth progression and poor outcome [27]. To
compare the expression of HDACs in primary rhabdoid
tumors and normal brain tissue we analyzed RNA
expression profiles of AT/RT tissue [25] and normal
brain tissue (Figure 1A and B and Additional file 1:
Figure S1) [26] from datasets available in the GEO
database [25,26]. Several HDAC including HDAC1, 2, 5,
6, 9 and SIRT1 are highly expressed in primary AT/RT
(Figure 1A and B, Additional file 1: Figure S1).
Group 1 HDACs (including HDAC1, 2 and 3) are
highly expressed in embryonic stem cells (ESCs) and
down regulated during differentiation (Figure 1C) [28].
Comparing protein expression in different SMARCB1
negative rhabdoid tumor cell lines (A204, G401, BT16,
BT12) with ESCs (OG2; as a control with known highly
expressed HDAC1 and HDAC2) demonstrate that group
1 HDAC levels are similarly expressed in rhabdoid
tumors and ESC (Figure 1D).
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Figure 1 Expression of HDACs in rhabdoid tumors. A and B. HDACs are highly expressed on RNA level in primary rhabdoid tumors
(n = 23) in comparison to differentiated brain tissue (n = 169) using available gene expression profiles of AT/RT [24] and different normal
brain tissues [26]. C. HDAC1 and HDAC2 are highly expressed in mouse embryonic stem cells (ESC cell line OG2) and are down
regulated after five days of differentiation (without LIF). D. Western-Blots of SMARCB1 negative rhabdoid tumor cell lines (BT12, BT16,
A204, G401) show high expression of HDAC 1 and HDAC 2, which is comparable to the expression of these HDACs in embryonal stem
cells (OG2).
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are highly expressed in SMARCB1 negative primary
tumors and tumor cell lines.The non-selective histone deacetylase inhibitor SAHA
induces reversible G2-arrest and apoptosis in SMARCB1
negative tumors
To evaluate whether high expression levels of HDACs
correlate with cell cycle progression in rhabdoid cells
we inhibited HDACs using the non-selective HDAC
inhibitor (HDACi) SAHA (suberoylanilindehydroxamic
acid) [9]. HDACi cause strong inhibition of cell
growth in high-risk embryonal tumors of the central
nervous system, including rhabdoid tumors [9,29].
Here we demonstrate that SAHA transiently (after
18 h) induces G2 arrest (Figure 2B, dashed, green line
and Table 3). In contrast to published data demon-
strating that the G2 arrest due to HDACi maybe a
sign of resistance of cell lines to HDACi [30],
rhabdoid tumor cell lines overcome the G2 arrest after
72 h (Figure 2B, dotted, blue line). After overcoming G2
arrest (Figure 2A and Additional file 2: Figure S2a)
apoptosis is induced (Figure 2B and Additional file 2:
Figure S2b).SAHA induces expression of RB-, MYC- and
pluripotency-associated genes
One major goal of our investigation was to identify
potential combinatorial approaches of SAHA with other
compounds based on molecular in vitro findings.
To analyze known deregulated pathways in rhabdoid
tumors, like RB and MYC, we performed microarray
analysis of A204 after treatment with HDAC inhibitor
SAHA. With a threshold of a 2-fold change we detected
1125 genes downregulated and approximately the same
number of genes upregulated (1.119 genes). We analyzed
known deregulated pathways in rhabdoid tumors, like
cdk4/6-cyclinD-RB- and MYC, using gene set enrich-
ment analysis (GSEA). We expected due to the observed
growth arrest that these pro-proliferative pathways were
downregulated after HDACi treatment [31]. Surprisingly
these gene sets (MYC, RB, stem cell programs;
Figures 3A-C) were not downregulated, but instead
even more pronounced and highly significantly enriched
following SAHA application. In these gene sets we
demonstrated that target genes of MYC (Figure 3A), the
RB-pathway (Figure 3B and Additional file 3: Figure S3)
and genes associated with pluripotency (Figure 3C) are
upregulated in SAHA-treated cells, indicating that not
only apoptosis but also pro-proliferative pathways are
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Figure 2 Functional effects of SAHA in rhabdoid tumor cells. A. Flow cytometry analysis: After 18 h treatment, SAHA (10 μM) induces G2
arrest and the formation of multinuclear cells (dashed line) after 18 h treatment in A204. After 72 h this G2 arrest is reversed (dotted line).
B. SAHA (10 μM) treatment results in induction of apoptosis after 72 h. C. Gene ontology of RNA Microarrays show that many genes involved in
"cell cycle", "DNA damage" and "chromosome segregation" are affected due to SAHA treatment
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A204 and G401 rhabdoid tumor cell lines using qPCR
(Additional file 3: Figure S3).
SAHA synergizes with fenretinide in inhibiting rhabdoid
cell growth
Treatment of rhabdoid tumor cell line A204 with
SAHA upregulates RB- and MYC- target genes and
the pluripotency-associated program controlled by EZH2.
These genes and gene pathways induce pro-proliferative
signals in rhabdoid tumors [21,32]. Based on these results
we developed a combined targeting strategy. We tested
treatment of SAHA in combination with tamoxifen and
fenretinide. Both compounds affect the transcription as well
as the protein stability of cyclin D1 [33,34]. FurthermoreTable 3 Shows %-values of G1-, S-, G2-phase cells of two
different rhabdoid tumor cell lines (A204, G401) treated
with 10 μM SAHA for 18 h or 72 h
Cell line G1-phase % S-phase % G2-phase %
A204 control 57.0 +/− 1.2 21.1 +/− 0.9 22.0 +/− 2.3
A204 SAHA 18 h 43.3 +/− 2.1 10.5 +/− 0.6 46.3 +/− 3.4
A204 SAHA 72 h 79.1 +/− 1.9 5.3 +/− 0.4 15.6 +/− 0.9
G401 control 45.8 +/− 1.0 39.2 +/− 1.6 14.9 +/− 0.9
G401 SAHA 18 h 56.4 +/− 7.6 12.8 +/− 0.2 30.8 +/− 2.6
G401 SAHA 72 h 76.2 +/− 5.5 10.3 +/− 2.8 13.5 +/− 0.6we combined SAHA with conventional chemotherapy
(doxorubcin).
The Rb-pathway is controlled by phosphorylation of Rb
by cdk4/6/cyclin D1. Dragnevet al showed that targeting
cyclin D1 by fenretinide leads to G0-arrest and apoptosis in
rhabdoid cell lines [34]. We compared cell proliferation
effects of SAHA in rhabdoid cell lines as a single compound
and combined treatment using SAHA with drugs that
inhibit cyclinD1 (fenretinide and tamoxifen). The combin-
ation of these two groups of compounds demonstrated
strong synergistic effects resulting in a significant
decrease of the IC50 values compared to the IC50 of
HDACi alone (Figure 4A-C and Table 1). The combin-
ation of 4-Hydroxytamoxifen (4-OH-Tam) and HDACi
showed strong synergism, however the combination of
fenretinide with HDACi reduces the IC50 values of the
HDACi to a nanomolar range. Different HDAC inhibitors
(SAHA, TSA, M344) in combination with fenretinide or
tamoxifen in different rhabdoid tumor cell lines (Figure 4A-
C and Table 1) showed strong synergistic effects. Using high
concentrations of these inhibitors no synergism is observed
due to cell toxicity of each single compound.
We additionally tested a treatment strategy combining
doxorubicin with SAHA. This resulted in a clear reduction
of doxorubicin IC50 values (Figure 4E and F; Table 2).
Using apoptosis assays we demonstrated, that the combin-
ation of SAHA and cyclinD1 inhibitors acts synergistically
due to induction of apoptosis (Figure 5A-F and Table 4).
NES 1.964
p < 0.001
FDR < 0.005
Myc target genesA Stem cell-associated genesB
NES 3.177
p < 0.001
FDR < 0.001
NES 2.436
p < 0.001
FDR < 0.001
Rb associated genes C
rhabdoid tumor plus SAHA rhabdoid tumor plus SAHA rhabdoid tumor plus SAHA
Figure 3 SAHA induces pro-proliferative programs. A–C. Microarrays were performed after treatment of rhabdoid tumor cell line A204 for
12 h with HDAC inhibitor SAHA. Gene set enrichment analysis (GSEA) [23,24] demonstrate that gene sets of MYC (A), Rb associated (B) and stem
cell associated (C) are positively enriched in SAHA-treated rhabdoid tumor cell line A204. Genes on the X-axis show the overlap between the
defined gene set and the regulated genes in the experiment. NES- negative enrichment score; FDR- false discovery rate (for brief description of
statistics see http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html).
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Conventional chemotherapeutics remain disappointing in
the treatment of rhabdoid tumors [35], making alternative
approaches highly needed. Rhabdoid tumors seem to
lack other mutations than those found in SMARCB1−6 −4 −2 0 2 4 6 −6 −4 −2
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Figure 4 Synergistic growth inhibition using SAHA with fenretinide a
A, B, C. HDACi (SAHA, M344, TSA) were used in concentrations ranging fro
was used in the same increasing concentration (0.01 μM to 100 μM). In the
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Figure 5 HDACi and fenretinide act synergistic on induction of apoptosis. A204 cells were treated for 72 h with HDACi SAHA (1 μM, 10 μM),
fenretinide (4HPR) (1 μM, 10 μM) or combinations of both compounds. Low concentrations (1 μM) of SAHA (B) or fenretinide (C) as single
treatment do not induce apoptosis compared to control (A). High concentrations (10 μM) of SAHA (D) or high concentrations of fenretinide (E),
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http://www.biomedcentral.com/1471-2407/13/286inhibitors (HDACi)) [9,11,38]. The rationale to use HDACi
in rhabdoid tumors is simple. First, several HDACs (includ-
ing HDAC 1, 2, 5, 6, 9 and SIRT1) are, like in many other
tumor entities [1,2], overexpressed in rhabdoid tumors.
Second, unselective HDACi inhibit cell growth, induce
apoptosis and autophagy in rhabdoid tumor cell lines
[9,38,39]. Third, HDACi lead to increased acetylation ofTable 4 Shows percentage of rhabdoid tumor cell lines (A204
of treatment with SAHA as a single compound or in combina
Cell line Control SAHA 1 μM SAHA
A204
% surviving cells 85.1 +/− 2.6 87.5 +/− 0.2 66.7 +
% early apoptosis 4.8 +/− 0.1 4.1 +/− 0.2 8.5 +/
% late apoptosis 10.1 +/− 2.5 8.4 +/− 0.3 24.8 +
G401
% surviving cells 90.3 +/− 0.8 91.2 +/− 1.5 64.7 +
% early apoptosis 5.2 +/− 0.6 5.1 +/− 0.9 23.6 +
% late apoptosis 4.5 +/− 0.2 3.8 +/− 0.7 11.7 +histones making chromatin more accessible to transcription
factors. SMARCB1, one of the core subunits of the SWI/
SNF complex, is involved in ATP-dependent chromatin re-
modeling and modulation of accessibility of chromatin to
transcription factors. As HDAC inhibition has been shown
to restore imprinted tumor suppressors such as CDKN1C
in rhabdoid tumors [39], we hypothesized that HDACi, G401) surviving, in early or in late apoptosis after 72 h
tion with 4HPR
10 μM 4HPR 1 μM 4HPR 10 μM SAHA 1 μM
4HPR 1 μM
/− 0.6 87.8 +/− 1.4 49.1 +/− 1.1 40.2 +/− 0.8
− 0.2 6.2 +/− 1.0 7.7 +/− 0.5 6.9 +/− 0.4
/− 1.5 8.3 +/− 0.7 43.1 +/− 0.7 6.9 +/− 0.4
/− 2.9 92.3 +/− 2.2 60.0 +/− 2.2 62.9 +/− 3.2
/− 0.9 4.1 +/− 1.2 26.9 +/− 0.7 27.3 +/− 1.3
/− 2.1 3.6 +/− 1.0 13.1 +/− 1.4 9.8 +/− 4.2
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http://www.biomedcentral.com/1471-2407/13/286might generally compensate the missing chromatin
remodeling function caused by SMARCB1 loss. We
investigated if HDAC inhibition leads to general restoration
of known deregulated pathways in rhabdoid tumor cell
lines (like MYC- or RB-pathways). Gene set enrichment
analysis (GSEA) demonstrated that gene programs, which
are deregulated by loss of SMARCB1 in rhabdoid tumors
(MYC, cyclin D1 and the pluripotency program) are further
upregulatedfollowing SAHA treatment. These results
suggest that HDAC inhibitors not only restore imprinted
tumor suppressor genes, like CDKN1C [39], but also, as an
“unselective transcription activator” increase expression of
deregulated oncogenes in rhabdoid tumors. Based on
these results we developed a combined targeting strategy
using SAHA with conventional chemotherapeutics and
compounds affecting cyclin D1-expression. The cdk4/cdk6/
cyclin D1 pathway is directly controlled by SMARCB1
[17,20,32]. Cyclin D1 forms a complex with cdk4/cdk6,
which than phosphorylates Rb, thereby activates E2F1 and
promotes cell cycle progression [40].
Combined targeted therapy of rhabdoid tumors makes
sense from a molecular biology and from a clinical point
of view. In other tumor entities including a subset of
medulloblastomas individual pathways such as the sonic
hedgehog pathway (SHH) seem to drive tumorigenesis
[41]. This type of medulloblastoma has been shown in vivo
to be highly responsive to small molecular compounds
specifically inhibiting the sonic hedgehog pathway [42].
In rhabdoid tumors the situation might be somewhat
different as biallelic mutation of the chromatin remodelingSNF5/ 
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Figure 6 Model of synergism of HDACi and fenretinide in rhabdoid tu
deregulating different tumor pathways like cyclin D-Rb-pathway and “EZH2
induces apoptotic cell death. On the other hand HDAC inhibition induces
this tumor entity (like cyclinD1 and “stem cell program”). 6. HDAC inhibitio
HDAC mediated cyclin D induction by fenretinide results in dramatic induc
synergizes in the induction of apoptosis.factor SMARCB1 deregulates multiple tumor pathways
(SHH, polycomb mediated pathways and Rb mediated
pathways) (Figure 6). As we have demonstrated inhibition
of one deregulated process (e.g. HDAC inhibition) may fail
to target other deregulated cascades or even upregulate
those pathways (like cdk4/6/cyclin D) due to an “unselect-
ive” transcriptional activation induced by HDACi. The
current knowledge of the function of molecular pathways,
the clinical behavior of rhabdoid tumors and our presented
results make combined targeted therapy highly attractive
and necessary for rhabdoid tumors. Inhibition of cyclinD1
and HDAC seems to affect two different deregulated targets
in rhabdoid tumors, act synergistically and might be an at-
tractive therapeutic approach for rhabdoid tumor treatment.
HDAC inhibitors as well as fenretinide have been eval-
uated in recent clinical phase I/II studies.
The bioavailability of fenretinide in children has been
discussed controversially. In a recent study in pediatric
neuroblastoma patients on fenretinide showed low
bioavailability [43]. New formulations of fenretinide are
presently evaluated [43].
Currently, over 100 phase I/II clinical trials are under-
way evaluating the safety and efficacy of HDAC inhibi-
tors [44,45]. Clinical approaches with single use of
HDACi show side effects like myelosuppression, fatigue
and other toxicity and demonstrate only moderate ef-
fects on tumor growth of most tumor entities tested so
far [45].
SAHA has been the first HDACi approved by the FDA
and has been tested in several clinical trials. In clinicalSNF5/ 
INI1 
Cell death 
CyclinD EZH2
„stem cell 
program“ 
„Rb 
program“ 
HDI B
mors. A. Loss of INI1 in rhabdoid tumors lead to tumor formation by
-stem cell program”. B. HDAC inhibition in rhabdoid tumor cell lines
genes and pathways which are known to be already deregulated in
n induces Rb-program by induction of CDK4/6/cyclin D1. Blocking
tion of apoptosis. The combined inhibition of HDACs and cyclin D
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http://www.biomedcentral.com/1471-2407/13/286studies the effect of single use of HDACi seems to be
minor, so combined strategies of SAHA with other
compounds are tested [29]. In adult AML patients phase
II studies showed that combined treatment of vorinostat
(SAHA) with idarubicine and cytarabine is safe [46].
Other phase I/II studies demonstrated the safety of SAHA
in combinations with paclitaxel and bevacizumab [47],
with gemtuzumab [48] and bortezomib [49]. Vorinostat in
pediatric patient cohorts has been well tolerated [50].Conclusion
To summarize our results we have demonstrated that
1. HDACi not only restore tumor suppressor genes like
CDKN1C, but also induce pro-proliferative genes
like CyclinD1, MYC and pluripotency associated genes
2. therapy of HDACi with cyclinD1 inhibitors and
combined use of HDACiwith conventional
chemotherapy demonstrates strong synergism on
inhibition of tumor cell growth.
These experiments provide the rationale for a promising
new therapeutic approach for the treatment of therapy
resistant rhabdoid tumors.Additional files
Additional file 1: Figure S1. HDACs are highly expressed on RNA level
in primary rhabdoid tumors (n = 23) in comparison to differentiated brain
tissue (n = 169) using available gene expression profiles of AT/RT [24] and
different normal brain tissues [26]. In addition to Figure 1 HDAC 5, HDAC
6 and SIRT1 are significantly upregulated in rhabdoid tumors compared
to normal brain tissue.
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treatment, SAHA (10 μM) induces G2 arrest and the formation of
multinuclear cells (dashed line) after 18 h treatment in G401. After 72 h
this G2 arrest is reversed (dotted line). B. SAHA (10 μM) treatment results
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treated with SAHA (10 μM) for 12 h. QPCR shows upregulation of
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